Endothelial Nitric Oxide Synthase Mediates the Cerebrovascular Effects of Erythropoietin in Traumatic Brain Injury by Jovany Cruz Navarro et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ORIGINAL RESEARCH ARTICLE
published: 09 October 2014
doi: 10.3389/fimmu.2014.00494
Endothelial nitric oxide synthase mediates the
cerebrovascular effects of erythropoietin in traumatic brain
injury
Jovany Cruz Navarro1, Shibu Pillai 1, Lucido L. Ponce1, MaiVan1, Jerry Clay Goodman2,3* and
Claudia S. Robertson1
1 Department of Neurosurgery, Baylor College of Medicine, Houston, TX, USA
2 Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX, USA
3 Department of Neurology, Baylor College of Medicine, Houston, TX, USA
Edited by:
Pietro Ghezzi, Brighton and Sussex
Medical School, UK
Reviewed by:
Barbara Viviani, University of Milan,
Italy
Kursad Genc, Dokuz Eylül University,
Turkey
*Correspondence:
Jerry Clay Goodman, Department of
Pathology and Immunology, Baylor
College of Medicine MS: BCM315,
One Baylor Plaza, Houston, TX 77030,
USA
e-mail: jgoodman@bcm.edu
Background: Erythropoietin (Epo) improves post-traumatic cerebral blood flow (CBF),
pressure autoregulation, and vascular reactivity to L-arginine. This study examines the
dependence of these cerebral hemodynamic effects of Epo on nitric oxide generated by
endothelial nitric oxide synthase (eNOS).
Methods: Using laser Doppler flow imaging, CBF was monitored in wild-type (WT) and
eNOS-deficient mice undergoing controlled cortical impact followed by administration of
Epo (5000 U/kg) or normal saline.
Results: Cerebral blood flow decreased in all groups post-injury with the greatest reduc-
tions occurring at the impact site. Epo administration resulted in significantly higher CBF
in the peri-contusional sites in the WT mice [70.2±3.35% in Epo-treated compared to
53±3.3% of baseline in saline-treated mice (p<0.0001)], but no effect was seen in the
eNOS-deficient mice. No CBF differences were found at the core impact site where CBF
dropped to 20–25% of baseline in all groups.
Conclusion: These differences between eNOS-deficient and WT mice indicate that the
Epo mediated improvement in CBF in traumatic brain injury is eNOS dependent.
Keywords: erythropoietin, traumatic brain injury, nitric oxide, nitric oxide synthase, neuroprotection, cerebral
blood flow
INTRODUCTION
Traumatic brain injury (TBI) remains a major public health prob-
lem in the United States. Each year, an estimated 1.7 million people
sustain some kind of TBI (1). More than 50,000 people die, and a
larger number of head injured patients suffer permanent disability.
Despite many promising experimental neuroprotection experi-
ments, there is presently no effective treatment that promotes
functional recovery in clinical TBI (2).
A substantial body of evidence has shown that erythropoietin
(Epo) has extra-erythropoietic activities including neural protec-
tive effects against a wide variety of acute experimental insults,
including spinal cord ischemia and trauma (3, 4), cerebral ischemia
(5), bilateral carotid occlusion (6), retinal ischemia caused by
uncontrolled intracranial pressure (7), subarachnoid hemorrhage
(8), and subdural hematoma (9). Administration of Epo and
Epo-analogs in experimental models of TBI leads to functional,
morphological, and cognitive recovery that has been attributed to
a several cytoprotective mechanisms including inhibition of apop-
tosis, anti-oxidant and anti-inflammatory actions, improved tissue
oxygenation due to vascular effects, and stimulation of neurogen-
esis and angiogenesis (10–21). In the present study, we examined
the effect of Epo on cerebral blood flow (CBF) and the dependence
of this effect on endothelial nitric oxide synthase (eNOS) following
controlled cortical impact (CCI).
BACKGROUND
Erythropoietin is a 34-kDa glycoprotein consisting of 165 amino
acids residues, synthesized mainly by the fetal liver and adult
kidney that is responsible for the proliferation, survival, and differ-
entiation of erythroid progenitor cells (22, 23). Epo and erythro-
poietin receptor (EpoR) expression in the neonatal and adult brain
are up-regulated during tissue hypoxia through an oxygen-sensing
pathway mediated by hypoxia-inducible factors (24, 25). Epo acts
by binding to a transmembrane receptor (EpoR) that belongs to
the type I cytokine family, causing dimerization of the receptor,
activating Janus-tyrosine-kinase-2 (JAK-2) that leads to several
downstream signaling pathways involved in the hematopoietic and
extra-hematopoietic effects of Epo (23, 26, 27).
The mechanism of Epo neuroprotection is not entirely clear,
and several pathways may be involved, including cerebrovascu-
lar effects through alterations in nitric oxide (NO) production by
eNOS. In ischemia models, this neuroprotection may be medi-
ated by hypoxia-inducible factor 1 (HIF-1) activating its target
genes Epo, EpoR, and vascular endothelial growth factor (VEGF)
(28–30). Alternatively, it has been suggested that Epo acts indi-
rectly on endothelial cells via activation of the VEGF receptor
system, which is the most important specific regulator of endothe-
lial growth and a major angiogenesis factor. In vitro studies,
suggest that Epo is a promising candidate in the treatment of
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cerebral aneurysms by increasing the expression of eNOS and
VEGF (31). Epo administration to coronary artery endothelial
cells up-regulates eNOS activity leading to enhance NO produc-
tion (32). In an isolated rat heart ischemia-reperfusion model,
pretreatment with Epo provides cardioprotection that is depen-
dent on NO (33). NO also has an important neuroprotectant role
in TBI. In rodent models of TBI, administration of l-arginine
increases NO levels in cerebral microdialyzate, restores CBF to
near pre-injury levels and reduces the resulting contusion vol-
ume (34). Pre-injury administration of Epo in an experimental
TBI model in rats treated with l-arginine results in a significant
CBF recovery, likely through a mechanism involving eNOS activ-
ity (18). In experimental intracerebral hemorrhage, Epo reduces
inflammation around the hematoma and activates eNOS possibly
leading to improved perfusion (35). When diffuse axonal injury
is coupled with hypoxia, Epo administration results in improved
motor and cognitive performance, improved neuritic sprouting,
and less corpus callosum thinning (36).
The purpose of this study was to evaluate the role of eNOS in
the vascular effects of Epo after CCI in wild type (WT) compared
to eNOS knock-out mice. Our hypothesis was that Epo mediated
effects on cerebrovascular physiology are eNOS dependent.
MATERIALS AND METHODS
This protocol was approved by the institutional animal proto-
col review committee, using guidelines for humane care and use
of animals that were developed for the National Institutes of
Health (NIH).
CEREBRAL BLOOD FLOW EXPERIMENTS
A total of 56 adult male WT eNOS+/+ mice (C57BL/6J, n= 28)
and homozygous eNOS-deficient mice (B6129P2-Nos tm I Unc/J
with a C57BL/6 genetic background, n= 28; Jackson Laboratories,
Bar Harbor, ME) were used to study the CBF response after Epo
administration during the first 2 h of monitoring after experimen-
tal TBI. eNOS-deficient animals used in this experiment were the
offspring of mating between heterozygous eNOS-deficient mice.
The eNOS-deficient mice were produced using 1.2 kb neomycin
cassette inserted into eNOS replacing 129 base pairs of exon 12 of
the gene, disrupting the calmodulin binding site of the eNOS and
introducing a premature stop codon in the transcripts. Disruption
of the eNOS gene was confirmed by PCR. eNOS protein in cere-
bral cortex determined by western blotting was 40% that seen in
WT animals.
eNOS-deficient and WT mice (14 mice per group) were ran-
domly treated with Epo (5000 U/kg) or 0.5 ml of normal saline
(NS) administered intra-peritoneally (IP) 5 min after the con-
trolled cortical injury. The different experimental groups included
the following:
eNOS+/−[NS]= eNOS-deficient mice treated with NS
eNOS+/−[Epo]= eNOS-deficient mice treated with Epo
WT-[NS]=Wild-type mice treated with NS
WT-[Epo]=Wild-type mice treated with Epo
The mice were anesthetized with 5% isoflurane in 100% oxy-
gen in a vented anesthesia chamber and maintained on
2% isoflurane for the duration of the experiment using a
volume-controlled ventilator (Hugo Sachs Elektronik-Harvard
Apparatus, March-Hugstetten, Germany) adjusted to obtain and
end-tidal CO2 level [EtCO2] between 35 and 40 mm Hg moni-
tored with microcapnography (Columbus Instruments, Colum-
bus, OH, USA). Rectal temperature was maintained between 36
and 37°C using a heat pad and a rectal thermistor. Blood pressure
was monitored via femoral artery cannulation.
Baseline mean arterial pressure (MAP) and CBF were obtained
15 min prior to the cortical impact and thereafter, MAP was mon-
itored at 30-s intervals. CBF was measured immediately after
Epo or NS injection at 5 min after CCI and then at 30, 60, 90,
and 120 min post-injury using a non-invasive laser Doppler flow
(LDF) scanner (PIM3 System, Perimed AB Stockholm, Sweden).
Periscan PIM3 measures the total microcirculatory blood per-
fusion including the perfusion in capillaries, arterioles, venules,
and shunting vessels. Measurements from this instrument are
expressed as arbitrary perfusion units (PU). To enable compar-
ison of results, perfusion changes were expressed as percentage
of baseline measurements. The LDF device was positioned 15 cm
above the head, and PUs were measured in regions of interest
(ROIs) ipsi- and contra-lateral to the injury. The ROIs con-
sisted of the site of the impact, cerebral cortex adjacent to the
impact site (peri-contusional), and the contra-lateral cerebral
hemisphere.
Controlled cortical impact injury was produced as previously
described (34). In brief, after craniectomy and dural exposure, the
3 mm diameter impactor tip was positioned perpendicular to the
exposed surface of the brain at an angle of 45° to the vertical. CCI
(3 m/s, 1.5 mm deformation, 100 ms of duration) was performed
using a voltage driven impactor (Benchmark Stereotaxic Impactor,
myNeuroLab, St Louis, MO, USA).
STATISTICAL ANALYSIS
Outcome assessments that were repeated over time such as CBF
were estimated using a mixed modeling procedure for analysis
of variance to estimate changes in means of variables between
groups (SAS Software System). MAP was analyzed using repeated
measures two-way analysis of variance (RM ANOVA).
RESULTS
MEAN ARTERIAL PRESSURE
Figure 1 summarizes the changes in blood pressure that
occurred following CCI. WT mice showed an initial MAP
of 76.75± 1.4 mm Hg compared to 97.17+ 0.39 mm Hg in the
eNOS-deficient animals (p< 0.05). eNOS-deficient mice started
from a higher baseline blood pressure that remained con-
sistently higher throughout the experiment because of toni-
cally reduced vasodilatation, but these animals had a greater
relative drop (15%) in MAP from baseline at the end of
the 2 h monitoring period. Following treatment, WT ani-
mals had MAP measurements that remained closer to base-
line values than the eNOS-deficient animals (genotype effect,
p< 0.001; time effect, p< 0.001; time × genotype interaction,
p< 0.001). At the end of the monitoring period, MAP averaged
86.35± 4.48 and 82.42± 3.42 mm Hg in the Epo/Saline eNOS
deficient treated groups, respectively; compared to 73.35+ 1.83
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FIGURE 1 | Hemodynamic response to the controlled cortical impact
(first arrow) followed by administration of the assigned treatment
(second arrow). (A) Mean arterial pressure (MAP) changes during the
experiment. The animals that were deficient in eNOS had a higher pre-injury
MAP and had a greater drop in MAP after injury than the wild-type animals.
When the group × time interaction was significant, symbols indicate which
treatments were significantly different among the treatments’ groups by the
Holm-Sidak post hoc test. (B–D) Cerebral blood flow response measured by
laser Doppler in the core (B), contra-lateral (C) and peri-contusional
(D) cerebral cortex. The core had a severe persistent drop in CBF regardless
of the animal genotype or treatment group. The contra-lateral cortex showed
a small to no decline followed by increased perfusion in all groups. In the
peri-contusional regions, Epo treatment effect was seen in the WT animals
but not in the eNOS-deficient animals (N =14 per group).
and 70.42± 2.09 mm Hg in the Epo/Saline WT treated animals,
respectively (p< 0.05, Holm-Sidak test).
CEREBRAL HEMODYNAMICS
Following cortical injury, CBF decreased in all treatment groups,
with the greatest reductions occurring at the core impact site
with less reduction in the peri-contusional cortex and least in the
contra-lateral cortex. CBF fell in the impact site from 100% to a low
value between 10 and 15% in all treatment groups by 2 h after cor-
tical injury. No significant blood flow differences were found over
time or by genotype at the core impact site (p> 0.05) (Figure 1B).
Although not significant, a trend for better CBF recovery contra-
lateral to the injury was observed over time favoring the WT
animals (Figure 1C). Significant genotype and treatment dif-
ferences in CBF were found only in the peri-contusional sites.
Reduction in CBF values in the peri-contusional sites was sim-
ilar between treatment groups immediately after cortical injury.
Subsequently, peri-contusional CBF declined to 50% of baseline
in the saline-treated animals and the Epo-treated eNOS-deficient
animals, but Epo administration resulted in significantly higher
CBF recovery in the peri-contusional region in the WT mice
(70± 3.3% in Epo-treated groups compared to 53± 3.35% in
saline-treated mice; p< 0.05) (Figure 1D). The results of the sta-
tistical analyses are summarized in Table 1. In the peri-contusional
(penumbral) area, there is a significant treatment effect and geno-
type effect but the interaction indicates that each depends on the
other. There is also a significant change over time that depends on
the genotype. There is no effect of Epo in the eNOS± genotype
but the Epo effect is significantly greater in the eNOS WT geno-
type. These differences are most notable between pre-injury and
pre-injection and the time points 30, 60, 90, and 120 min after
injury.
DISCUSSION
Cerebral pressure autoregulation is the intrinsic ability to main-
tain constant CBF over a range of blood pressures, and metabolic
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Table 1 | Multi-level statistical model for the cerebral blood flow (CBF) data comparing the EPO-treated and the saline-treated groups in the two
genotypes of mice.
Effect Core Peri-contusional Contra-lateral
NDF DDF F-value p NDF DDF F-value p NDF DDF F-value p
Cerebral blood flow
Treatment 1 52 0.7 0.4056 1 52 5.29 0.0255 1 52 2.77 0.1023
Genotype 1 52 0.92 0.3418 1 52 7.35 0.0091 1 52 2.13 0.1508
Treatment*genotype 1 52 0.65 0.4248 1 52 8.00 0.0066 1 52 0.08 0.7832
Time 5 260 80.59 <0.0001 5 260 39.26 <0.0001 5 260 10.22 <0.0001
Time*treatment 5 260 0.19 0.9652 5 260 1.09 0.3684 5 260 0.39 0.8548
Time*genotype 5 260 0.99 0.4221 5 260 6.91 <0.0001 5 260 1.32 0.2572
Time*treatment*genotype 5 260 1.50 0.189 5 260 1.11 0.357 5 260 0.35 0.8804
NDF, numerator degrees of freedom; DDF, denominator degrees of freedom.
Multi-level statistical model of the CBF in the core, penumbra, and contra-lateral cerebral cortex. In the peri-contusional (penumbral) area, there is a significant
treatment effect and genotype effect but the interaction indicates that each depends on the other. There is also a significant change over time that depends on the
genotype. There is no effect of Epo in the eNOS±genotype but the Epo effect is significantly greater in the eNOS WT genotype (N=14 per group: eNOS± treated
with normal saline, eNOS± treated with Epo, eNOS treated with normal saline, and eNOS treated with Epo).
cerebral autoregulation is the ability of the brain to locally adjust
CBF to meet cerebral metabolic requirements (37). Cerebral pres-
sure autoregulation is disrupted in TBI and this may be due to
dysfunction of endothelial NO production.
Nitric oxide plays an important role in a number of general
physiological processes of the brain, such as the maintenance of
basal vasomotor tone, selective neuroprotection, synaptogenesis,
and synaptic plasticity; therefore, NO has multiple and complex
roles in the pathophysiology of TBI. NO is a cell membrane-
permeable free radical synthesized from the amino acid l-arginine
by the enzyme NOS (38). In TBI, both excess and deficiency of
NO can potentially result in detrimental effects. Depletion of NO
produced by eNOS may result in inadequate cerebral perfusion,
whereas excess NO produced by nNOS and iNOS could poten-
tially lead to neurotoxicity and cellular injury. Such changes in
cerebral NO metabolism have been implicated in the pathophysi-
ological changes occurring after TBI. Triphasic (high-low-high)
changes in cerebral concentration of NO after TBI have been
described in experimental and clinical studies. A brief rise in NO
concentration lasting seconds to minutes immediately after injury
in experimental models is followed by a protracted decrease (0.5–
6 h) in NO concentrations that may partly account for the low CBF
observed during this period after injury. This is followed by a late
phase (>6 h) in which an elevation in cerebral NO is associated
with a return to normal or even elevated levels of CBF. Increased
expression of iNOS protein in cerebrovascular smooth muscles has
been observed during this phase, and CSF levels of NO have been
reported to peak between 20 and 42 h after TBI (39). During the
early phase, a period of relative deficiency in NO and a low level of
CBF, the administration of l-arginine has been shown to improve
CBF and neurological outcome in models of TBI (34). Administra-
tion of l-arginine in patients after severe TBI induced an increase
in internal carotid artery flow volume, which was larger at 48 h
than at 12 h, and tended to be larger in the less injured hemisphere
at both time periods, suggesting that dysfunction of cerebrovascu-
lar endothelium plays a role in the reduced CBF observed after TBI
(40). Some of the variability in patient outcome that occurs follow-
ing severe TBI may result from eNOS polymorphisms (41). During
the late peak in NO after TBI due to the activity of iNOS, the inhi-
bition of iNOS has been neuroprotective in experimental models
of TBI (42–44). l-Arginine administration may or may not result
in an increase of CBF after CCI depending upon whether or not
the mice had been hemorrhaged (45). It is well documented that
CBF and cerebral autoregulation are heterogeneous after TBI and
tend to be reduced in the immediate vicinity of a contusion (46).
Our experimental model focuses on the early phase after CCI
and previous studies have shown a lower plasma and micro-
dialysate NO concentration in the eNOS-deficient mice compared
to WT mice. Our study also showed a sustained decrease in
post-traumatic CBF in eNOS-deficient mice compared to WT
mice. eNOS-deficient mice had significant lower CBF in peri-
contusional areas of the brain in spite of maintaining higher MAP
compared to WT mice. Moreover, earlier studies have demon-
strated that eNOS-deficient mice have higher MAP than do WT
mice but comparable CBF (47), these finding have been confirmed
in the present study. It has also been shown that cortical blood flow,
measured by laser Doppler, is reduced by about 70% from base-
line in eNOS-deficient mice and by about 50% in WT mice 2 h
after trauma (48, 49). These values are comparable to the relative
reduction in blood flow observed at 2 h after CCI in our present
study. CBF changes detected by LDF were only consistently signif-
icant in the peri-contusional areas of the brain (e.g., penumbra),
which are vulnerable to additional secondary insults (e.g., hypoxia,
hypotension). Importantly, these same areas are often considered
as potentially salvable cerebral tissue that could contribute in the
recovery and outcome after TBI.
Discovery of Epo and EpoR in many non-erythroid organs and
tissues such as endothelial cells, reproductive organs, heart, gas-
trointestinal tract, muscle cells, and the central nervous system
(CNS) suggests a wide variety of actions (23, 50, 51). Differ-
ent cell types (neurons, glia and endothelial cells) in the nervous
system produce Epo and express EpoR, and Epo appears to have
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multiple actions in the nervous system. Epo has neuroprotec-
tive effects after ischemic, hypoxic, metabolic, neurotoxic, and
excitotoxic stress in the nervous system. This neuroprotection
potentially operates simultaneously at several levels in the cen-
tral nervous system, such as limiting the production of reactive
oxygen species and glutamate, neurotransmission modulation,
reversal of vasospasm, promoting angiogenesis, preventing apop-
tosis, reduction of inflammation, and stem cell recruitment. Our
study indicates that some of the neuroprotective effect results from
maintenance of CBF by an eNOS dependent mechanism. Simi-
larly, NOS dependency of the neuroprotective effects of Epo has
been described in the restoration of working memory deficits in
rats subjected to global transient ischemia (52). Interestingly, in
the stable tubule only polypeptide (STOP) null mouse model that
displays neurochemical and behavioral aspects of schizophrenia,
Epo results in an improvement in cognitive function that is NO
dependent. These studies of working memory restoration in tran-
sient global ischemia and cognitive function in STOP mice used
pharmacological inhibition of NOS, so it is not possible to discern
if the effects were mediated by eNOS or nNOS.
Studies of the effects of Epo in organs other than the brain as
well as in vitro endothelial cells suggest that protective effects are
eNOS dependent. In cultured lung endothelial cells, hypoxia leads
to constriction but in the presence of Epo there is up-regulation
of eNOS with increased NO production leading to vasorelaxation.
In addition, the NO leads to up-regulation of EpoR in these cells
suggesting a coordinated response of these signaling molecules
(53). In studies of sepsis in which tumor necrosis factor induces
microvascular inflammation in striated muscle, Epo ameliorates
the microvascular damage by an eNOS dependent mechanism
but the protective effect is independent of iNOS (54). Similarly,
Epo prevents sepsis-related acute kidney in rats by up-regulating
eNOS (55). In ischemic musculocutaneous skin flaps, Epo admin-
istration up-regulates eNOS and the protective effect is abrogated
by administration of eNOS inhibitors (56). Administration of
Epo has also been shown to reduce the depth and area of sec-
ondary burn progression (57). These extra-hematopoietic eNOS
dependent protective actions may result, at least in part, from
vasodilation with increased blood flow.
The purpose of the present study is to identify the effect of
Epo on CBF changes measured by LDF after TBI and the depen-
dence of these changes on eNOS. Binding of Epo to its receptor
(EpoR) on the endothelial cells of the cerebral vasculature leads to
phosphorylation of JAK-2 that activates the PI3-K/AKT pathway
resulting in eNOS activation by phosphorylation. The increased
activity of eNOS increases NO production resulting in cerebral
vasodilation and increased CBF. Epo administration resulted in
significantly higher LDF in the peri-contusional sites only in the
WT mice and eNOS-deficient mice showed poorer LDF recov-
ery after injury in the peri-contusional sites with both treatment
groups (Epo vs. saline; p> 0.05) having comparable LDF values
at 120 min after CCI. The relatively rapid increase in CBF follow-
ing Epo administration after CCI is likely due to direct signaling
pathways in the cerebral vasculature leading to eNOS activation
and NO production rather than other slower Epo effects that
depend on transcriptional regulation. The rapid time course of
changes in CBF also indicates direct physiological effect rather
than impaired vascular remodeling in the eNOS-deficient animals
or up-regulation of inducible or neuronal NOS. Previous stud-
ies have shown that restoration of penumbral blood flow using
NO augmentation is associated with better behavioral, histologi-
cal, and contusion volume outcome following CCI. A recent study
using inhaled NO in the CCI suggests that CBF can be restored
without disrupting cerebral autoregulation, increasing intracranial
pressure, or protein nitrosylation, and that augmenting NO by this
means results in reduced contusion volume and better behavioral
outcome (58).
There are some technical limitations of this study. CBF was
measured using laser Doppler which provides arbitrary PUs rather
than quantitative CBF that can be expressed in ml/mg/min; there-
fore, we measured relative perfusion. The major advantage of using
laser Doppler is that this technique enables rapid serial measure-
ments. Lundband et al. measured cortical blood flow following
CCI in eNOS-deficient mice using [14C]-iodoantipyrine at 3 and
24 h after injury (49). The magnitude of CBF change they observed
at 3 h was similar to that we observed at 30 min, 1 h and 2 h after
injury.
Our study supports the importance of eNOS and NO in the very
early stages in the pathophysiology of TBI in maintaining adequate
CBF as well as the positive effect of Epo in re-establishing the CBF
in the penumbra within 2 h after the injury by a NO dependent
mechanism. These findings support the potential for very early
administration of Epo or Epo agonists in the management of TBI.
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